Most Popular
-
1
[Feature] Constant competition drives Koreans to despair
-
2
Korea’s hostility to short selling may scare global investors away
-
3
Samsung-Apple rivalry renewed as first AI iPhone debuts
-
4
[Pressure points] Workplace communication: To emoji or not to emoji?
-
5
First lady likely to escape 'Dior bag' indictment
-
6
So many epic performances, so few places to hold them
-
7
Korean teachers handling larger classes, but starting pay lags behind OECD average
-
8
[Grace Kao] American redemption vs. Korean punishment for BTS’ Suga
-
9
Celltrion eyes new production plant, aims for W5tr in sales
-
10
HD Hyundai, Hanwha on edge as KDDX probe nears conclusion
-
BreathMo®: The New Generation ECMO system Revealed at ASAIO Conference
SUZHOU, China, July 22, 2023 /PRNewswire/ -- Last month, the American Society for Artificial Internal Organs (ASAIO) 68th Annual Meeting was successfully held in San Francisco. magAssist's product, BreathMo® was highlighted in the meeting. Dr. Dong Guo from Beijing Anzhen Hospital, introduced the innovation of the device featured in a study titled "A 14-Day In-Vivo Evaluation of a Newly Developed Maglev ECMO System BreathMo®, " demonstrating its effectiven
July 22, 2023
-
Insilico Medicine Nominates Preclinical Candidate of Inhalation Solution for ISM001-055, the First Generative AI IPF Drug
Insilico Medicine merges nebulizer device with AI-driven drug discovery; Potential advantages for the inhalation solution include a smaller effective dose, larger safety window and reduced side effects; As demonstrated in preclinical studies, the inhalation solution of ISM001-055 is well tolerated with good anti-fibrotic and anti-inflammatory efficacy, favorable safety and pharmacokinetic (PK) profiles, and no local or systemic toxicity observed. NEW YORK and HONG KONG, July 22, 2023 /
July 22, 2023
-
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients in Europe die annually from the disease² If approved by the European Commission, ORSERDU would be the first and only treatment specifically indicated for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations ESR1 mutations are present in up to 40% of ER+, HE
July 22, 2023
-
TUMI AND HIGHSNOBIETY JOIN FORCES ON DISRUPTIVE CONTENT SERIES, BRINGING THE TUMI | McLAREN COLLECTION TO THREE FORMULA 1 GRAND PRIX RACES ACROSS THREE CONTINENTS
Captured through the lens of Highsnobiety, this three-part series entitled 'The High Road' will chronicle a journey in McLaren's supercars through Britain, Singapore, and Las Vegas, and bring to life three unique stories with unexpected talent and eye-catching visuals. NEW YORK, July 21, 2023 /PRNewswire/ -- Today, international travel and lifestyle brand TUMI debuted The High Road, a content series created in partnership with Highsnobiety, which will highlight the brand's on
July 22, 2023
-
LG Innotek published the 2022-2023 Sustainability Report
Achieved 20% carbon neutrality within one year after the declaration and increased shareholder-friendly policies such as the 10% dividend payout ratio Increased investment in R&D by 33% from the previous year to strengthen the competitiveness of future business SEOUL, South Korea, July 21, 2023 /PRNewswire/ -- LG Innotek (CEO Jeong Cheol-dong) announced on the 21st that it had published the '2022-2023 Sustainability Report' that covers the performance of ESG (Environmental&mid
July 22, 2023
-
Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA
SAN DIEGO, July 21, 2023 /PRNewswire/ -- Invivoscribe is excited to announce that the LeukoStrat® CDx FLT3 Mutation Assay has been approved by the U.S. Food and Drug Administration (FDA) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to receive treatment with Daiichi Sankyo's VANFLYTA® (quizartinib). The LeukoStrat CDx FLT3 Mutation Assay identifies FLT3-ITD positive AML patients who may be treated with
July 21, 2023
-
H3C Partners with Universiti Pendidikan Sultan Idris to Launch Industry-Leading Computer Networking Program
H3C and Universiti Pendidikan Sultan Idris (UPSI) has signed an MoU to promote H3C Academy, a comprehensive program designed to equip students with the essential knowledge and skills to design, build, and maintain computer networks The program aims to provide Malaysians with excellent certification programs and training courses to enhance their expertise in the networking field KUALA LUMPUR, Malaysia, July 21, 2023 /PRNewswire/ -- H3C and Universiti Pendidikan Sultan Idris
July 21, 2023
-
GCL and LandSpace Join Forces to Propel World's First Methane-Powered Rocket to Orbit
JIUQUAN, China, July 21, 2023 /PRNewswire/ -- Bearing the GCL's slogan "Bringing Green Power to Life", Zhuque-2 (ZQ-2 Y2), a methane-fueled rocket built by LandSpace in collaboration with GCL System Integration Technology Co., Ltd. ("GCL", SHE:002506), successfully entered orbit after launching at 9 a.m. (0100 GMT) from the Jiuquan Satellite Launch Center in northwest China. Bringing Green Power To Life GCL, a leading one-stop renewable energy service prov
July 21, 2023
-
International friendship cities -- Innovation Leads Rural Revitalization in Zaozhuang, Shandong
ZAOZHUANG, China, July 21, 2023 /PRNewswire/ -- A news report from The Publicity Department of the CPC Zaozhuang Municipal Committee: Zaozhuang City of East China's Shandong Province is striving to become a model city of the province's rural revitalization. From June 14th to 16th, the on-site promotion conference on innovation leading rural revitalization was held in Zaozhuang. The city has previously been approved to construct a national demonstration zone for the su
July 21, 2023
-
Accor accelerates in Japan with agreement to operate 23 properties
ACCOR SIGNS MILESTONE AGREEMENT WITH EBISU RESORT LLC, WITH 23 PROPERTIES SET TO JOIN THE GROUP'S HOTEL NETWORK BY Q2 2024 PARIS, July 21, 2023 /PRNewswire/ -- Accor's presence in Japan is set to double while hotel openings gain momentum throughout the region. With travel and tourism surging once again on a global scale, countries such as Japan, Singapore, Vietnam, and surrounding regions such as China, are experiencing a significant influx of foreign travelers, as well as increasing domesti
July 21, 2023
-
134th Canton Fair New Highlights: Optimization and Adjustment of Exhibition Sections
GUANGZHOU, China, July 21, 2023 /PRNewswire/ -- The 134th China Import and Export Fair ("Canton Fair" or "the Fair") is scheduled to be held both onsite and online in a merged format on October 15, boasting new highlights and features with optimized exhibition sections that adapted to global market trends and demands to better serve global visitors. The on-site exhibition, which is to be held in 3 phases at the Canton Fair Complex in Guangzhou, will adjust the sch
July 21, 2023
-
GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent
Striving to further expand its territory to Africa and the Middle East from Southeast Asia and Latin America "Will create synergy between international procurement market and private markets of individual countries so as to boost sales and profitability" YONGIN, South Korea, July 21, 2023 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company, announced on the 18th that its quadrivalent flu vaccine called GC FLU Quadrivalent Pre-filled syringe inj. has be
July 21, 2023
-
Trip.com Group and Chope partner to provide instant restaurant reservations to Southeast Asian-bound travellers
Travellers can now book over 3,000 restaurants across Singapore, Indonesia, and Thailand via Trip.com and Ctrip The partnership boosts discoverability of high-end restaurants, local-approved finds, and hidden gems across key tourist destinations such as Bali and Phuket F&B businesses can look forward to a boom in traffic from gourmands who are eager to expand their palate SINGAPORE, July 21, 2023 /PRNewswire/ -- Trip.com Group, a leading global travel platform, and Chope, As
July 21, 2023
-
SK hynix Becomes First Semiconductor Company in Korea to Win Both ISO Compliance, Anti-Bribery Management System Certifications
ISO certification ensures company's commitment to legal compliance "Aims to continuously grow into a semiconductor company trusted by stakeholders" SEOUL, South Korea, July 21, 2023 /PRNewswire/ -- SK hynix Inc. (or "the company", www.skhynix.com) announced today that it has been awarded the ISO 37301 compliance management system* and ISO 37001 anti-bribery management system** certifications issued by the British Standards Institute (BSI). * ISO 37301: Internat
July 21, 2023
-
WEKA Introduces Guarantees for Cloud Cost Savings and On-Prem Performance
CAMPBELL, Calif., July 21, 2023 /PRNewswire/ -- WekaIO (WEKA), the data platform provider for performance-intensive workloads, today unveiled two new guarantees for WEKA® Data Platform customers: the WEKA Half Price Guarantee for cloud deployments and the WEKA 2X Performance Guarantee for on-premises deployments. Organizations are increasingly finding that legacy data infrastructure is ill-suited to the needs of next-generation applications like artificial intelligence (AI), machine l
July 21, 2023
-
US FDA Grants Orphan Drug Designation of SN Bioscience's Nano Anti-Cancer Drug 'SNB-101' for Small Cell Lung Cancer
SEONGNAM, South Korea, July 21, 2023 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on July 19 that the US FDA had granted an orphan drug designation for small cell lung cancer for SNB-101 (API: SN-38), a new polymer nanoparticle drug under development. SNB-101 is the world's first nanoparticle anticancer drug that has been developed extremely insoluble SN-38 into polymer nanoparticles. It has been approved for phase 1 clinical trials in the US (NCT04640480) and Ko
July 21, 2023
-
COP28 President-Designate and Prime Minister of Bangladesh, Sheikh Hasina, call for the world's most vulnerable to be placed at the heart of climate action
Prime Minister Hasina agreed to champion the food agenda of COP28 and underscored how crucial food systems transformation and agricultural innovation is to sustainable development. Dr Al Jaber met with Bangladesh Prime Minister, Sheikh Hasina during a trip to the capital of Bangladesh, Dhaka Dr. Sultan shared his ambitions and action agenda for COP28 with the Prime Minister, while underscoring his commitment to put people, lives, and livelihoods at the heart of the climate agend
July 21, 2023
-
REALTY ONE GROUP NAMED TOP GLOBAL FRANCHISE
The UNBrokerage, with its ONE-of-a-Kind Brand and COOLTURE, Once Again Makes Entrepreneur's Prominent Top 200 Global Franchise Brands 2023 LAS VEGAS, July 21, 2023 /PRNewswire/ -- Realty ONE Group, a modern, purpose-driven lifestyle brand and ONE of the fastest growing franchises in the world, was once again named to Entrepreneur's 2023 Top Global Franchises list proving the fierce allure of its COOLTURE, business coaching and branding go far beyond the U.S. real estate industry and is now s
July 21, 2023
-
Build Smart. Go Elite! GIGABYTE AORUS ELITE graphics cards and motherboards elevate the PC gaming experience to elite levels
TAIPEI, July 20, 2023 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, its AORUS ELITE series motherboards have long been the go-to choice for PC gamers and enthusiasts seeking exceptional value to elevate their gaming experience to the next level. Expanding on the immense success of the AORUS ELITE products, GIGABYTE now introduces the AORUS ELITE series graphics cards, featuring the same distinguished design concept with class-leading performance. These latest additions inclu
July 21, 2023
-
ADVANCEMENTS IN TREATMENT, DIAGNOSIS AND RISK REDUCTION STRATEGIES HIGHLIGHTED AT ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
AMSTERDAM, July 20, 2023 /PRNewswire/ -- New research reported at the Alzheimer's Association International Conference® (AAIC®) 2023 covered the breadth of Alzheimer's disease and dementia research, including advancements in treatment, early and accurate diagnosis, and our understanding of risk factors for Alzheimer's and other dementias. AAIC is the premier annual forum for presentation and discussion of the latest Alzheimer's and dementia research. This year's conference
July 21, 2023